Primary studies related to this topic

loading
12 References (6 articles) Revert Studify

Primary study

Unclassified

A randomized intervention of montelukast for postbronchiolitis: effect on eosinophil degranulation

blocked
Journal Journal of Allergy and Clinical Immunology
Year 2010

This article is included in 1 Systematic review Systematic reviews (1 reference) 1 Broad synthesis Broad syntheses (1 reference)

Loading references information

Primary study

Unclassified

Montelukast as an episodic modifier for acute viral bronchiolitis: A randomized trial

Journal Allergy and asthma proceedings : the official journal of regional and state allergy societies
Year 2010
Links Pubmed DOI

This article is included in 1 Systematic review Systematic reviews (1 reference) 2 Broad syntheses Broad syntheses (2 references)

Loading references information
This study was designed to evaluate the effect of once-daily montelukast therapy on the clinical progress and the cytokine profile of patients with acute viral bronchiolitis. A randomized, double-blind, placebo-controlled trial included 85 patients (mean age, 3.5 ± 2.35 months), clinically diagnosed as first-episode acute bronchiolitis in addition to 10 healthy controls of matched age and sex. Patients were randomly assigned to receive either montelukast (4-mg sachets; n = 47) or placebo (n = 38) daily from the time of admission until discharge. The primary outcome measure was the length of hospital stay (LOS), and clinical severity scores (CSs) and changes in plasma levels of interferon gamma and interleukin-4 were secondary outcomes. LOS for the montelukast group was found to be significantly lower than that of the placebo group (p < 0.05). This effect was also found at nonsignificant levels among patients with a positive family history of asthma or allergy. Moreover, cases receiving montelukast showed lower CSs all through the hospital stay that were significant in the first 24 hours (p < 0.05). Montelukast is probably of benefit as an episodic modifier in infants with acute viral bronchiolitis. Copyright © 2010, OceanSide Publications, Inc.

Primary study

Unclassified

A randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation.

blocked
Journal The Journal of pediatrics
Year 2010
Links Pubmed DOI

This article is included in 2 Systematic reviews Systematic reviews (2 references) 2 Broad syntheses Broad syntheses (2 references)

Loading references information
Objective: To investigate the effect of montelukast on eosinophil degranulation and recurrent wheezing episodes in post-respiratory syncytial virus (RSV) bronchiolitis. Study design: Two hundred infants (age, 6-24 months) who were hospitalized with their first episode of acute RSV bronchiolitis were randomized in a double-blind, placebo-controlled, parallel comparison of 4-mg montelukast granules (RSV-MONT group) or matching placebo (RSV-PLC group) administered for 3 months. Serum eosinophil-derived neurotoxin (EDN) levels were measured (primary outcome), and recurrent wheezing was documented (secondary outcome) for 12 months. Comparisons were made with control subjects (control group, n = 50). Results: At the end of the 3-month treatment period, the RSV-PLC group (n = 71) exhibited significantly elevated EDN levels (P < .0001), and the RSV-MONT group (n = 79) showed significantly decreased EDN levels (P < .01) when compared with the initial levels. As a result, EDN levels in the 2 RSV groups significantly differed at this point (P < .0001) and remained different for the entire 12-month follow-up period. Cumulative recurrent wheezing episodes at 12 months were significantly lower in the RSV-MONT group (P = .039). Conclusion: Montelukast treatment reduces eosinophil degranulation and is associated with a decrease in recurrent wheezing episodes in post-RSV bronchiolitis. © 2010 Mosby, Inc. All rights reserved.

Primary study

Unclassified

Montelukast in the Treatment of Bronchiolitis, A Multi-center, Randomized, hree-blind, Placebo-controlled Trial

Authors BAI Jun , XU Pei-ru
Journal 中国循证医学杂志 (Chinese Journal of Evidence-Based Medicine)
Year 2010
Links DOI

This article is included in 1 Systematic review Systematic reviews (1 reference) 1 Broad synthesis Broad syntheses (1 reference)

Loading references information
OBJECTIVE: To study the efect of montelukast for improving bronchial hyperresponsiveness (BHR) in treatment of bronchiolitis. METHODS: Four hundreds infants, 3 to 24 months old, hospitalized with acute bronchiolitis in three Hospitals (Urumqi Children’s Hospital, Pediatrics Department of First Ailiated Hospital of Xinjiang Medical University, and Pediatrics Department of Army General Hospital) from January, 2007 to January, 2008, were randomly assigned into four groups: placebo group ( RESULTS: =92), budesonide group ( CONCLUSIONS: =91), montelukast short-course group (7 days,

Primary study

Unclassified

Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis.

Journal Acta paediatrica (Oslo, Norway : 1992)
Year 2009
Links Pubmed DOI

This article is included in 2 Systematic reviews Systematic reviews (2 references) 2 Broad syntheses Broad syntheses (2 references)

Loading references information
AIM: To evaluate the long-term effect of montelukast on symptoms of cough and wheeze following RSV bronchiolitis. METHODS: Fifty eight patients (aged < or = 24 months) hospitalized with a first episode of RSV bronchiolitis were enrolled in this double blind prospective randomized trial comparing montelukast (n = 31) vs placebo (n = 27). RESULTS: During the 3-month treatment period, there were no statistical significant differences between the two groups for symptom-free days and nights (48.5 [interquartile range 33.0.0-66.0] for montelukast vs 57.0 [29.0-71.0] for placebo p = 0.415) nor disease-free days and nights (44.5 days [26.0-54.0] vs 53.0 [22.3-71.0]; p = 0.266). During the 1 year follow-up, there were 41 exacerbations in the montelukast group vs 54 exacerbations in the placebo group (p = 0.57). Time to first exacerbation was not different. Number of unscheduled visits and need to start inhaled steroids were comparable in the two groups. CONCLUSION: Treatment with montelukast after hospital admission for RSV bronchiolitis in children younger than 2 years of age did not reduce symptoms of cough and wheeze. We cannot exclude that a subgroup of children may, however, benefit from this treatment.

Primary study

Unclassified

A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis

blocked
Journal Pediatrics
Year 2009

This article is included in 2 Systematic reviews Systematic reviews (2 references) 2 Broad syntheses Broad syntheses (2 references)

Loading references information

Primary study

Unclassified

Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children.

Journal American journal of respiratory and critical care medicine
Year 2008
Links Pubmed DOI

This article is included in 2 Systematic reviews Systematic reviews (2 references) 2 Broad syntheses Broad syntheses (2 references)

Loading references information
RATIONALE: A pilot study (Bisgaard H; Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003;167:379-383) reported the efficacy of montelukast in post-respiratory syncytial virus (RSV) bronchiolitic respiratory symptoms. OBJECTIVES: To evaluate the efficacy and safety of montelukast, 4 and 8 mg, in treating recurrent respiratory symptoms of post-RSV bronchiolitis in children in a large, multicenter study. METHODS: This was a double-blind study of 3- to 24-month-old children who had been hospitalized for a first or second episode of physician-diagnosed RSV bronchiolitis and who tested positive for RSV. Patients (n = 979) were randomized to placebo or to montelukast at 4 or 8 mg/day for 4 weeks (period I) and 20 weeks (period II). The primary end point was percentage symptom-free days (%SFD; day with no daytime cough, wheeze, and shortness of breath, and no nighttime cough). MEASUREMENTS AND MAIN RESULTS: No significant differences were seen between montelukast and placebo in %SFD over period I: mean +/- SD for placebo and for montelukast at 4 and 8 mg were 37.0 +/- 30.7, 38.6 +/- 30.4, and 38.5 +/- 29.9, respectively. Least-squares mean differences (95% confidence interval) between montelukast (4 mg) and placebo and between montelukast (8 mg) and placebo were 1.9% (-2.9, 6.7) and 1.6% (-3.2, 6.5), respectively. Secondary end points were similar across treatments. Both doses were generally well tolerated. During the first two treatment weeks, average %SFD was approximately 29%. In post hoc analyses of patients (n = 523) with persistent symptoms (%SFD &lt; or = 30% over Weeks 1-2), differences in %SFD were seen between montelukast and placebo over Weeks 3-24: difference were 5.7 (0.0, 11.3) for montelukast (4 mg) minus placebo and 5.9 (0.1, 11.7) for montelukast (8 mg) minus placebo. CONCLUSIONS: In this study, montelukast did not improve respiratory symptoms of post-RSV bronchiolitis in children.

Primary study

Unclassified

A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis

blocked
Journal Pediatrics
Year 2008
Links Pubmed DOI

This article is included in 1 Systematic review Systematic reviews (1 reference) 2 Broad syntheses Broad syntheses (2 references)

Loading references information
BACKGROUND. Cysteinyl leukotrienes are implicated in the inflammation of bronchiolitis. Recently, a specific cysteinyl leukotriene receptor antagonist, montelukast (Sin-gulair [MSD, Haarlem, Netherlands]), has been approved for infants in granule sachets. OBJECTIVE. Our goal was to evaluate the effect of montelukast on clinical progress and on cytokines in acute bronchiolitis. METHODS. This was a randomized, placebo-controlled, double-blind, parallel-group study in 2 medical centers. Fifty-three infants (mean age: 3.8 ± 3.5 months) with a first episode of acute bronchiolitis were randomly assigned to receive either 4-mg montelukast sachets or placebo, every day, from hospital admission until discharge. The primary outcome was length of stay, and secondary outcomes included clinical severity score (maximum of 12) and changes in type 1 and 2 cytokine levels (including interleukin4/IFN-y ratio as a surrogate for the T-helper 2/T-helper 1 ratio) in nasal lavage. RESULTS. Both groups were comparable at baseline, and cytokine levels correlated positively with disease severity. There were neither differences in length of stay (4.63 ± 1.88 [placebo group] vs 4.65 ± 1.97 days [montelukast group]) nor in clinical severity score and cytokine levels between the 2 groups. No differences in interleukin 4/IFN-y ratio between the 2 groups were seen. There was a slight tendency for infants in the montelukast group to recover more slowly than those in the placebo group (clinical severity score at discharge: 6.1 ± 2.4 vs 4.8 ± 2.2, respectively). CONCLUSIONS. Montelukast did not improve the clinical course in acute bronchiolitis. No significant effect of montelukast on the T-helper 2/T-helper 1 cytokine ratio when given in the early acute phase could be demonstrated. Copyright © 2008 by the American Academy of Pediatrics.

Primary study

Unclassified

Post hoc analysis of the effect of montelukast in treating post RSV bronchiolitic respiratory symptoms in children [Abstract]

blocked
Journal European respiratory journal
Year 2007
Links pesquisa.bvsalud

This article is included in 1 Systematic review Systematic reviews (1 reference) 1 Broad synthesis Broad syntheses (1 reference)

Loading references information
asthma; children

Primary study

Unclassified

Randomized, placebo-controlled study of montelukast for treatment of post-RSV-bronchiolitic respiratory symptoms in children

blocked
Journal Allergy
Year 2007
Links copsac.com

This article is included in 1 Systematic review Systematic reviews (1 reference) 1 Broad synthesis Broad syntheses (1 reference)

Loading references information